Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of MT-1303

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* RRMS as defined by the revised McDonald criteria~* Evidence of recent MS activity defined as either:~  * at least one documented relapse in the previous 12 months, OR~ * a positive gadolinium (Gd)-enhanced MRI scan within 3 months prior to screening, OR~ * at least two documented relapses in the previous 24 months with a positive Gd-enhanced MRI scan within the previous 12 months~* Expanded Disability Status Score (EDSS) score ≥0.0 and ≤5.5 points.~Exclusion Criteria:~* Primary progressive, secondary progressive or progressive relapsing MS at screening~* Disease duration \>15 years combined with an EDSS score ≤2.0~* Relapse of MS during the Screening Period~* History or known presence of other neurological disorders likely to render the subject unsuitable for the study~* History of any of a list of pre-defined cardiovascular diseases~* History or known presence of any significant central nervous system, infectious, metabolic, oncological, ophthalmological or respiratory system disease or illness likely to render the subject unsuitable for the study~* Previous exposure to any sphingosine 1-phosphate receptor modulator~* Receipt of a live vaccine or systemic corticosteroid use within 28 days prior to randomisation~* Previous treatment with beta-interferons or glatiramer acetate within 14 days prior to randomisation~* Previous treatment with intravenous immunoglobulin, plasmapheresis, certain immunosuppressants, lymphocyte-depleting therapy, total body irradiation or bone marrow transplantation~* Need, or likely need for, treatment with Class I or III anti-arrhythmic drugs or with heart-rate-lowering beta-blockers or calcium-channel blockers, or with any other drugs which can reduce the heart rate~* Evidence of significant anaemia, thrombocytopenia, leucopoenia or lymphocytopenia, renal or hepatic impairment~* Clinically significant electrocardiogram (ECG) findings.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- MT-1303-Low (Type: EXPERIMENTAL): MT-1303-Low Dose
- MT-1303-Middle (Type: EXPERIMENTAL): MT-1303-Middle Dose
- MT-1303-High (Type: EXPERIMENTAL): MT-1303-High Dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).